Literature DB >> 23698290

The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics.

Lydia Tan1, Frank E J Coenjaerts, Lieselot Houspie, Marco C Viveen, Grada M van Bleek, Emmanuel J H J Wiertz, Darren P Martin, Philippe Lemey.   

Abstract

Genomic variation and related evolutionary dynamics of human respiratory syncytial virus (RSV), a common causative agent of severe lower respiratory tract infections, may affect its transmission behavior. RSV evolutionary patterns are likely to be influenced by a precarious interplay between selection favoring variants with higher replicative fitness and variants that evade host immune responses. Studying RSV genetic variation can reveal both the genes and the individual codons within these genes that are most crucial for RSV survival. In this study, we conducted genetic diversity and evolutionary rate analyses on 36 RSV subgroup B (RSV-B) whole-genome sequences. The attachment protein, G, was the most variable protein; accordingly, the G gene had a higher substitution rate than other RSV-B genes. Overall, less genetic variability was found among the available RSV-B genome sequences than among RSV-A genome sequences in a comparable sample. The mean substitution rates of the two subgroups were, however, similar (for subgroup A, 6.47 × 10(-4) substitutions/site/year [95% credible interval {CI 95%}, 5.56 × 10(-4) to 7.38 × 10(-4)]; for subgroup B, 7.76 × 10(-4) substitutions/site/year [CI 95%, 6.89 × 10(-4) to 8.58 × 10(-4)]), with the time to their most recent common ancestors (TMRCAs) being much lower for RSV-B (19 years) than for RSV-A (46.8 years). The more recent RSV-B TMRCA is apparently the result of a genetic bottleneck that, over longer time scales, is still compatible with neutral population dynamics. Whereas the immunogenic G protein seems to require high substitution rates to ensure immune evasion, strong purifying selection in conserved proteins such as the fusion protein and nucleocapsid protein is likely essential to preserve RSV viability.

Entities:  

Mesh:

Year:  2013        PMID: 23698290      PMCID: PMC3700225          DOI: 10.1128/JVI.03278-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  74 in total

1.  The human respiratory syncytial virus matrix protein is required for maturation of viral filaments.

Authors:  Ruchira Mitra; Pradyumna Baviskar; Rebecca R Duncan-Decocq; Darshna Patel; Antonius G P Oomens
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

2.  Genetic variability and molecular evolution of the human respiratory syncytial virus subgroup B attachment G protein.

Authors:  Kalina T Zlateva; Philippe Lemey; Elien Moës; Anne-Mieke Vandamme; Marc Van Ranst
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

4.  Membrane orientation and oligomerization of the small hydrophobic protein of human respiratory syncytial virus.

Authors:  P L Collins; G Mottet
Journal:  J Gen Virol       Date:  1993-07       Impact factor: 3.891

5.  Analysis of respiratory syncytial virus strain variation in successive epidemics in one city.

Authors:  P A Cane; D A Matthews; C R Pringle
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

Review 6.  Unravelling the complexities of respiratory syncytial virus RNA synthesis.

Authors:  Vanessa M Cowton; David R McGivern; Rachel Fearns
Journal:  J Gen Virol       Date:  2006-07       Impact factor: 3.891

7.  Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection.

Authors:  L K Hallak; D Spillmann; P L Collins; M E Peeples
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

8.  Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus.

Authors:  Elaine M Castilow; Matthew R Olson; David K Meyerholz; Steven M Varga
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

9.  Improving the accuracy of demographic and molecular clock model comparison while accommodating phylogenetic uncertainty.

Authors:  Guy Baele; Philippe Lemey; Trevor Bedford; Andrew Rambaut; Marc A Suchard; Alexander V Alekseyenko
Journal:  Mol Biol Evol       Date:  2012-03-07       Impact factor: 16.240

10.  A counting renaissance: combining stochastic mapping and empirical Bayes to quickly detect amino acid sites under positive selection.

Authors:  Philippe Lemey; Vladimir N Minin; Filip Bielejec; Sergei L Kosakovsky Pond; Marc A Suchard
Journal:  Bioinformatics       Date:  2012-10-12       Impact factor: 6.937

View more
  40 in total

1.  Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.

Authors:  A Leemans; M De Schryver; W Van der Gucht; A Heykers; I Pintelon; A L Hotard; M L Moore; J A Melero; J S McLellan; B S Graham; L Broadbent; U F Power; G Caljon; P Cos; L Maes; P Delputte
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

2.  Conservation of G-Protein Epitopes in Respiratory Syncytial Virus (Group A) Despite Broad Genetic Diversity: Is Antibody Selection Involved in Virus Evolution?

Authors:  Alfonsina Trento; Leyda Ábrego; Rosa Rodriguez-Fernandez; Maria Isabel González-Sánchez; Felipe González-Martínez; Adriana Delfraro; Juan M Pascale; Juan Arbiza; José A Melero
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

3.  Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In Vitro.

Authors:  Patricia A Jorquera; Cynthia Mathew; Reena Ghildyal; Jennifer Pickens; Colin Williams; Jasmina M Luczo; Sharon Tamir; Ralph A Tripp
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

4.  Genetic Stability of Parainfluenza Virus 5-Vectored Human Respiratory Syncytial Virus Vaccine Candidates after In Vitro and In Vivo Passage.

Authors:  Shannon I Phan; Carolyn M Adam; Zhenhai Chen; Michael Citron; Xiaoping Liang; Amy S Espeseth; Dai Wang; Biao He
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

5.  A vulnerable, membrane-proximal site in human respiratory syncytial virus F revealed by a prefusion-specific single-domain antibody.

Authors:  Iebe Rossey; Ching-Lin Hsieh; Koen Sedeyn; Marlies Ballegeer; Bert Schepens; Jason S Mclellan; Xavier Saelens
Journal:  J Virol       Date:  2021-03-10       Impact factor: 5.103

Review 6.  Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design.

Authors:  Janyra A Espinoza; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

7.  Prefusion F-Based Polyanhydride Nanovaccine Induces Both Humoral and Cell-Mediated Immunity Resulting in Long-Lasting Protection against Respiratory Syncytial Virus.

Authors:  Laura M Stephens; Kathleen A Ross; Kody A Waldstein; Kevin L Legge; Jason S McLellan; Balaji Narasimhan; Steven M Varga
Journal:  J Immunol       Date:  2021-04-07       Impact factor: 5.422

8.  A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas.

Authors:  Brittani N Blunck; Letisha Aideyan; Xunyan Ye; Vasanthi Avadhanula; Laura Ferlic-Stark; Lynn Zechiedrich; Brian E Gilbert; Pedro A Piedra
Journal:  Vaccine       Date:  2021-01-26       Impact factor: 3.641

Review 9.  Nanoparticle vaccines against respiratory syncytial virus.

Authors:  Laura M Stephens; Steven M Varga
Journal:  Future Virol       Date:  2020-11-30       Impact factor: 1.831

10.  Recombinant subgroup B human respiratory syncytial virus expressing enhanced green fluorescent protein efficiently replicates in primary human cells and is virulent in cotton rats.

Authors:  Ken Lemon; D Tien Nguyen; Martin Ludlow; Linda J Rennick; Selma Yüksel; Geert van Amerongen; Stephen McQuaid; Bert K Rima; Rik L de Swart; W Paul Duprex
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.